Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis
Gastrointestinal cytomegalovirus (CMV) disease in ANCA-associated vasculitis is associated with significant morbidity. Studies should be performed to identify the epidemiology and risk factors for CMV disease in AAV so that vulnerable patients may be risk-stratified for consideration of preventive strategies such as surveillance and pre-emptive therapy or anti-viral prophylaxis. Given the absence of evidence-based guidelines for prevention of CMV disease in patients with AAV receiving potent immunosuppressive therapy, further risk-benefit studies are required to ascertain if preventive strategies will reduce CMV-related morbidity and mortality in individuals with AAV.
KeywordsCyclophosphamide Immunosuppressive agents Methylprednisolone Prophylaxis
Compliance with ethical standards
Jason Choo has served on Advisory Boards for Novartis and Pfizer with donation of honorarium to Singapore General Hospital to support research and education.
- 1.Soriano A, Smerieri N, Bonilauri S, de Marco L, Cavazza A, Salvarani C (2018) Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. Clin Rheumatol. https://doi.org/10.1007/s10067-017-3945-6
- 3.Lim CC, Tung YT, Tan BH, Lee PH, Mok IYJ, Oon L, Chan KP, Choo JCJ (2017) Epidemiology and risk factors for cytomegalovirus infection in glomerular diseases treated with immunosuppressive therapy. Nephrology (Carlton). https://doi.org/10.1111/nep.13071
- 5.Chanouzas D, Dyall L, Nightingale P, Ferro C, Moss P, Morgan MD, Harper L (2016) Valaciclovir to prevent cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis: study protocol for a randomised controlled trial. Trials 17(1):338CrossRefPubMedPubMedCentralGoogle Scholar